Vera Therapeutics, Inc.
A biotechnology company developing treatments for autoimmune and kidney diseases, Vera Therapeutics makes Trutakna (atacicept), a self-administered injectable for adults with IgA nephropathy, a kidney condition driven by the immune system. It began in 2016 as Trucode Gene Repair before rebranding to Vera — Latin for "truth," echoing its motto "truth in science" — and pivoting to immunology and kidney disease. Its lead drug won U.S. approval in 2026 as a first-in-class therapy for the condition.
Bought 3.21M
Bought 790.6K
Bought 1.71M
Bought 448.2K · Sold 1.05M
Bought 285.7K
Bought 1.24M
Bought 266.7K
Granted 9.9K · Sold 9.9K
Bought 727.3K
Bought 888.6K · Sold 834.5K
Bought 772.7K
Granted 741.7K · Sold 464.2K
Bought 606.1K · Sold 31.5K
Granted 211.7K · Bought 24.3K · Sold 123.4K
Granted 116.5K · Bought 5.7K · Sold 54.7K
Granted 20.0K · Sold 1.6K
Granted 51.9K · Sold 2.2K
Granted 53.0K · Sold 3.9K
Granted 46.9K · Sold 2.6K
Granted 77.5K · Sold 32.2K
Granted 42.4K
Granted 102.8K · Sold 102.7K
Granted 12.5K · Sold 1.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Enright Patrick GDirector · 9 transactions | — | 7.20M | — | 3.21M | — |
| Emster Kurt VonDirector · 3 transactions | — | 5.17Mas of May 2021 | — | 790.6K | — |
| Tammenoms Bakker Juliet +4 co-filers10% owner · 1 transaction | — | 5.14Mas of Feb 2023 | — | 1.71M | — |
| Commodore Capital LP10% owner · 2 transactions | — | 4.40Mas of Jan 2024 | — | 448.2K | 1.05M |
| Healy James +4 co-filers10% owner, Director, 10% owner · 1 transaction | — | 3.47Mas of Feb 2023 | — | 285.7K | — |
| Tammenoms Bakker Juliet +2 co-filers10% owner · 3 transactions | — | 3.43Mas of Feb 2022 | — | 1.24M | — |
| Healy James +3 co-filers10% owner, Director, 10% owner · 1 transaction | — | 3.18Mas of Feb 2022 | — | 266.7K | — |
| Abingworth Bioventures 8 LP +9 co-filers10% owner · 4 transactions | — | 2.96Mas of Aug 2022 | 9.9K | — | 9.9K |
| Healy James +3 co-filers10% owner · 2 transactions | — | 2.91Mas of May 2021 | — | 727.3K | — |
| Katabi MahaDirector · 9 transactions | — | 2.79Mas of Mar 2024 | — | 888.6K | 834.5K |
| Abingworth LLP10% owner · 2 transactions | — | 2.19Mas of May 2021 | — | 772.7K | — |
| Fordyce MarshallPRESIDENT AND CEO, Director · 146 transactions | — | 420.3K | 741.7K | — | 464.2K |
| Seidenberg Beth CDirector · 27 transactions | — | 135.6Kas of Oct 2024 | — | 606.1K | 31.5K |
| Grant SeanCHIEF FINANCIAL OFFICER · 36 transactions | — | 119.2K | 211.7K | 24.3K | 123.4K |
| Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR · 18 transactions | — | 75.8K | 116.5K | 5.7K | 54.7K |
| Skelton Laurence MatthewChief Commercial Officer · 2 transactions | — | 64.2K | 20.0K | — | 1.6K |
| Brenner RobertChief Medical Officer · 3 transactions | — | 50.9K | 51.9K | — | 2.2K |
| Carter Jason SChief Legal Officer · 2 transactions | — | 49.1K | 53.0K | — | 3.9K |
| Johnson David LeeChief Operating Officer · 3 transactions | — | 45.7K | 46.9K | — | 2.6K |
| Turner William D.Chief Regulatory Officer · 9 transactions | — | 45.3K | 77.5K | — | 32.2K |
| Wright-Mitchell JaneChief Legal Officer · 1 transaction | — | 42.4K | 42.4K | — | — |
| Curley JoanneChief Development Officer · 87 transactions | — | 27.0Kas of Aug 2023 | 102.8K | — | 102.7K |
| Cheng AndrewDirector · 1 transaction | — | 17.5Kas of May 2021 | — | — | — |
| Lin CeliaChief Medical Officer · 2 transactions | — | 11.0Kas of Aug 2023 | 12.5K | — | 1.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +8.27M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.